{"hands_on_practices": [{"introduction": "Understanding Autosomal Dominant Polycystic Kidney Disease (ADPKD) begins at the genetic level with the \"somatic second-hit\" hypothesis. This model explains why, in a person carrying one faulty gene copy in every cell, only a small fraction of kidney tubules form cysts. This practice will guide you through a probabilistic calculation to appreciate how rare, random genetic events in individual cells accumulate to cause disease [@problem_id:4801047].", "problem": "A patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) carries a germline heterozygous variant in the polycystin-1 gene ($PKD1$). In the somatic second-hit model of cyst initiation, a focal tubular epithelial cell can initiate a cyst when a subsequent somatic event (e.g., a mutation or loss of heterozygosity (LOH)) functionally inactivates the remaining wild-type allele. Consider a single tubular epithelial cell lineage that undergoes $N=10^{6}$ mitotic divisions over time. Suppose the per-division probability of a somatic second hit that inactivates the wild-type allele is $\\mu=1\\times 10^{-7}$, and assume independence of divisions with a constant per-division risk across the lineage.\n\nUsing first principles of probability for independent Bernoulli trials, derive from the complement rule the probability $P$ that at least one effective second hit occurs somewhere in this lineage. Then evaluate $P$ numerically for the given $\\mu$ and $N$. Express your answer as a decimal fraction and round to four significant figures. Finally, explain conceptually (not as part of the numerical answer) how this focal probability relates to mosaic cyst initiation in the context of a germline heterozygous $PKD1$ variant.", "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded in the accepted two-hit model of cystogenesis in Autosomal Dominant Polycystic Kidney Disease (ADPKD), well-posed with all necessary information provided, and objective in its formulation. The problem asks for the derivation and calculation of a probability based on a series of independent Bernoulli trials and a conceptual explanation of the result in a biological context.\n\nThe problem can be modeled as a sequence of $N$ independent Bernoulli trials, where each trial corresponds to a single mitotic division of a cell in the lineage. A \"success\" is defined as the occurrence of a somatic second hit that inactivates the wild-type $PKD1$ allele. The probability of success in any single trial is given as $\\mu$.\n\nLet $S_i$ be the event of a second hit occurring during the $i$-th division, for $i = 1, 2, \\dots, N$.\nThe probability of this event is $P(S_i) = \\mu$.\nThe event that no second hit occurs during the $i$-th division is the complement event, denoted $S_i^c$. Its probability is $P(S_i^c) = 1 - \\mu$.\n\nThe problem asks for the probability $P$ that at least one effective second hit occurs somewhere in the lineage of $N$ divisions. This can be expressed as the probability of the union of all success events:\n$$P = P(S_1 \\cup S_2 \\cup \\dots \\cup S_N)$$\nCalculating this directly is cumbersome. It is more straightforward to use the complement rule, as requested by the problem. The complement of \"at least one hit\" is \"zero hits\".\nLet $A$ be the event that at least one hit occurs in $N$ divisions. The complement event, $A^c$, is that no hits occur in any of the $N$ divisions.\n$$P(A) = 1 - P(A^c)$$\nThe event $A^c$ corresponds to the intersection of the events where no hit occurred in each individual division:\n$$A^c = S_1^c \\cap S_2^c \\cap \\dots \\cap S_N^c$$\nSince the divisions are assumed to be independent events, the probability of the intersection is the product of the individual probabilities:\n$$P(A^c) = P(S_1^c) \\times P(S_2^c) \\times \\dots \\times P(S_N^c) = \\prod_{i=1}^{N} P(S_i^c)$$\nSince $P(S_i^c) = 1 - \\mu$ for all $i$, this simplifies to:\n$$P(A^c) = (1 - \\mu)^N$$\nSubstituting this back into the complement rule, we obtain the desired expression for $P$:\n$$P = 1 - (1 - \\mu)^N$$\nThis is the derived probability that at least one effective second hit occurs in the lineage.\n\nNow, we evaluate $P$ numerically using the given values:\nNumber of divisions, $N = 10^6$.\nPer-division probability of a second hit, $\\mu = 1 \\times 10^{-7}$.\n\nSubstituting these values into the derived formula:\n$$P = 1 - (1 - 1 \\times 10^{-7})^{10^6}$$\n$$P = 1 - (1 - 0.0000001)^{1000000}$$\n$$P = 1 - (0.9999999)^{1000000}$$\nCalculating the value of the term $(0.9999999)^{1000000}$:\n$$(0.9999999)^{1000000} \\approx 0.90483736$$\nTherefore, the probability $P$ is:\n$$P \\approx 1 - 0.90483736 = 0.09516264$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $9$, $5$, $1$, and $6$. The fifth significant figure is $2$, which is less than $5$, so we do not round up.\n$$P \\approx 0.09516$$\n\nConceptually, this probability $P \\approx 0.09516$ (or about $9.5\\%$) represents the risk that a *single* tubular epithelial cell lineage, starting from a cell with a germline $PKD1$ mutation, will give rise to a cyst-initiating cell over the course of $10^6$ divisions. This risk for a single lineage is relatively low.\n\nHowever, the human kidney is composed of millions of renal tubules, each containing thousands of such epithelial cells. Each of these cells can be considered the progenitor of a distinct lineage, running an independent \"probabilistic experiment\". If there are, for example, $M$ such independent lineages in the kidneys, the probability that *at least one* of them initiates a cyst is $1 - (1-P)^M$. Given that $M$ is a very large number, this probability approaches $1$ (certainty), even though $P$ itself is small. This explains the high penetrance of the diseaseâ€”why individuals with a germline $PKD1$ mutation almost invariably develop numerous cysts. The cysts arise from focal, sporadic second-hit events, meaning the kidney tissue becomes a \"mosaic\" of a vast majority of cells that are heterozygous at the $PKD1$ locus (one hit) and a small number of clonal cell populations that are functionally null for $PKD1$ (two hits) and which go on to form the cysts. This calculated focal probability is the fundamental unit of risk that, when scaled up to the level of the entire organ, accounts for the clinical phenotype of ADPKD.", "answer": "$$\\boxed{0.09516}$$", "id": "4801047"}, {"introduction": "Following a \"second hit,\" the loss of functional polycystin proteins disrupts crucial cellular signaling pathways. One of the most important disruptions involves the regulation of intracellular calcium ($Ca^{2+}$) concentration, which in turn alters cell behavior. This exercise uses a simplified flux-balance model to quantify how a defect in the polycystin-2 channel can lead to the lowered cytosolic calcium levels characteristic of PKD cells [@problem_id:4824743].", "problem": "In autosomal dominant polycystic kidney disease, polycystin-2 (PC2) is a calcium-permeable channel whose loss-of-function lowers calcium influx. Consider a cell in which the basal cytosolic calcium concentration, denoted by $C(t)$, is governed by a steady-state flux balance between an influx mediated by PC2 and an efflux mediated by a calcium pump. Assume the following simplified, linear model based on core transport definitions:\n\n- The channel-mediated influx is $J_{\\text{in}}(C) = g\\,(C_{o} - C)$, where $g$ is an effective conductance parameter and $C_{o}$ is the extracellular calcium concentration.\n- The pump-mediated efflux is $J_{\\text{out}}(C) = k\\,C$, where $k$ is the pump extrusion rate constant.\n- Basal cytosolic calcium is the steady state $C^{*}$ for which $\\frac{dC}{dt} = 0$.\n\nA loss-of-function mutation in polycystin-2 reduces the effective conductance by a fraction $0.70$ relative to the wild-type value. Take $C_{o} = 1.5 \\times 10^{3}$ $\\mu\\text{M}$, $g_{\\text{WT}} = 2.7 \\times 10^{-4}$ $\\text{s}^{-1}$, and $k = 4.0$ $\\text{s}^{-1}$. Using the flux-balance framework described above, compute the basal cytosolic $Ca^{2+}$ concentration $C_{\\text{mut}}$ under PC2 loss-of-function. Express your answer in $\\mu\\text{M}$ and round your answer to four significant figures.", "solution": "The problem requires the calculation of the basal cytosolic $Ca^{2+}$ concentration in a cell with a loss-of-function mutation in the polycystin-2 (PC2) channel. The analysis will be based on the provided flux-balance model.\n\nFirst, we must validate the problem statement.\n\n**Step 1: Extract Givens**\n-   The cytosolic calcium concentration is denoted by $C(t)$.\n-   The channel-mediated influx is $J_{\\text{in}}(C) = g\\,(C_{o} - C)$.\n-   $g$ is the effective conductance parameter.\n-   $C_{o}$ is the extracellular calcium concentration.\n-   The pump-mediated efflux is $J_{\\text{out}}(C) = k\\,C$.\n-   $k$ is the pump extrusion rate constant.\n-   Basal cytosolic calcium is the steady state concentration $C^{*}$ for which $\\frac{dC}{dt} = 0$.\n-   A loss-of-function mutation in PC2 reduces the effective conductance by a fraction $0.70$ relative to the wild-type value, $g_{\\text{WT}}$.\n-   $C_{o} = 1.5 \\times 10^{3}$ $\\mu\\text{M}$.\n-   $g_{\\text{WT}} = 2.7 \\times 10^{-4}$ $\\text{s}^{-1}$.\n-   $k = 4.0$ $\\text{s}^{-1}$.\n-   The objective is to compute the basal cytosolic $Ca^{2+}$ concentration $C_{\\text{mut}}$ under the loss-of-function mutation.\n-   The final answer must be expressed in $\\mu\\text{M}$ and rounded to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, employing a standard and simplified biophysical model for ion concentration dynamics based on flux balance. The roles of channels (influx) and pumps (efflux) are correctly represented. The context regarding polycystic kidney disease and the function of PC2 is pathophysiologically correct. The problem is well-posed, providing all necessary mathematical definitions and parameter values to arrive at a unique solution. The language is objective and precise. The physical units are consistent: the rate constants $g$ and $k$ are in $\\text{s}^{-1}$, and the concentrations are in $\\mu\\text{M}$. The underlying differential equation, $\\frac{dC}{dt} = J_{\\text{in}} - J_{\\text{out}}$, is dimensionally consistent, where the fluxes are interpreted as rate processes contributing to the change in concentration. The problem is valid as it does not violate any of the specified invalidity criteria.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Solution Derivation**\nThe rate of change of the cytosolic calcium concentration, $C(t)$, is given by the net flux, which is the difference between the influx and efflux. Assuming a model where the rate of concentration change is directly proportional to the fluxes given:\n$$ \\frac{dC}{dt} = J_{\\text{in}}(C) - J_{\\text{out}}(C) $$\nSubstituting the given expressions for the fluxes:\n$$ \\frac{dC}{dt} = g\\,(C_{o} - C) - k\\,C $$\nThe basal cytosolic calcium concentration is defined as the steady-state concentration, $C^{*}$, where the concentration does not change over time. This corresponds to the condition $\\frac{dC}{dt} = 0$.\n$$ g\\,(C_{o} - C^{*}) - k\\,C^{*} = 0 $$\nThis equation represents the flux balance, where influx equals efflux:\n$$ g\\,(C_{o} - C^{*}) = k\\,C^{*} $$\nWe solve for the steady-state concentration $C^{*}$:\n$$ g\\,C_{o} - g\\,C^{*} = k\\,C^{*} $$\n$$ g\\,C_{o} = (k + g)C^{*} $$\n$$ C^{*} = \\frac{g\\,C_{o}}{k + g} $$\nThis general expression relates the steady-state concentration to the model parameters $g$, $k$, and $C_{o}$.\n\nThe problem specifies a loss-of-function mutation that reduces the effective conductance $g$ by a fraction $0.70$ relative to the wild-type value, $g_{\\text{WT}}$. The magnitude of the reduction is $0.70 \\times g_{\\text{WT}}$. The resulting mutant conductance, $g_{\\text{mut}}$, is therefore:\n$$ g_{\\text{mut}} = g_{\\text{WT}} - 0.70 \\times g_{\\text{WT}} = (1 - 0.70) \\times g_{\\text{WT}} = 0.30 \\times g_{\\text{WT}} $$\nWe are given $g_{\\text{WT}} = 2.7 \\times 10^{-4}$ $\\text{s}^{-1}$. We can calculate $g_{\\text{mut}}$:\n$$ g_{\\text{mut}} = 0.30 \\times (2.7 \\times 10^{-4} \\text{ s}^{-1}) = 0.81 \\times 10^{-4} \\text{ s}^{-1} $$\nNow we can compute the basal concentration for the mutant case, $C_{\\text{mut}}$, by substituting $g_{\\text{mut}}$ for $g$ in the general steady-state equation. We use the provided values for the parameters:\n-   $g_{\\text{mut}} = 0.81 \\times 10^{-4}$ $\\text{s}^{-1}$\n-   $C_{o} = 1.5 \\times 10^{3}$ $\\mu\\text{M}$\n-   $k = 4.0$ $\\text{s}^{-1}$\n\nThe expression for $C_{\\text{mut}}$ is:\n$$ C_{\\text{mut}} = \\frac{g_{\\text{mut}}\\,C_{o}}{k + g_{\\text{mut}}} $$\nSubstituting the numerical values:\n$$ C_{\\text{mut}} = \\frac{(0.81 \\times 10^{-4} \\text{ s}^{-1}) \\times (1.5 \\times 10^{3} \\text{ } \\mu\\text{M})}{4.0 \\text{ s}^{-1} + 0.81 \\times 10^{-4} \\text{ s}^{-1}} $$\nFirst, calculate the numerator:\n$$ \\text{Numerator} = (0.81 \\times 1.5) \\times 10^{-4+3} \\text{ } \\mu\\text{M} \\cdot \\text{s}^{-1} = 1.215 \\times 10^{-1} \\text{ } \\mu\\text{M} \\cdot \\text{s}^{-1} = 0.1215 \\text{ } \\mu\\text{M} \\cdot \\text{s}^{-1} $$\nNext, calculate the denominator:\n$$ \\text{Denominator} = 4.0 \\text{ s}^{-1} + 0.000081 \\text{ s}^{-1} = 4.000081 \\text{ s}^{-1} $$\nNotice that $g_{\\text{mut}}$ is several orders of magnitude smaller than $k$, which is typical for such physiological systems, ensuring that intracellular concentrations are kept low despite a large extracellular concentration.\n\nNow, compute the final value for $C_{\\text{mut}}$:\n$$ C_{\\text{mut}} = \\frac{0.1215 \\text{ } \\mu\\text{M} \\cdot \\text{s}^{-1}}{4.000081 \\text{ s}^{-1}} \\approx 0.03037461 \\text{ } \\mu\\text{M} $$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $3$, $0$, $3$, and $7$. The fifth significant figure is $4$, which is less than $5$, so we round down (i.e., we do not change the fourth significant digit).\n$$ C_{\\text{mut}} \\approx 0.03037 \\text{ } \\mu\\text{M} $$\nThis is the basal cytosolic $Ca^{2+}$ concentration under the PC2 loss-of-function mutation.", "answer": "$$ \\boxed{0.03037} $$", "id": "4824743"}, {"introduction": "The cumulative effect of countless cellular-level events is the progressive enlargement of the kidneys, a hallmark of ADPKD. Total kidney volume ($TKV$) has emerged as a powerful biomarker for predicting disease progression and qualifying patients for specific therapies. In this final practice, you will step into a clinical setting to calculate a height-adjusted TKV and use the Mayo imaging classification to stratify a patient's risk of progression [@problem_id:4321955].", "problem": "An adult patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) presents for imaging-based risk stratification. The kidneys show bilaterally enlarged, diffusely cystic parenchyma without segmental sparing, consistent with a typical ADPKD phenotype appropriate for application of the Mayo imaging classification. The following measurements are obtained:\n- Total kidney volume (TKV): $950 \\ \\mathrm{mL}$\n- Standing height: $1.70 \\ \\mathrm{m}$\n- Age: $35 \\ \\mathrm{years}$\n\nStarting from core definitions and well-tested facts, construct a TKV-based risk classification using the Mayo imaging classification for typical ADPKD and compute the height-adjusted total kidney volume (HtTKV). Encode the assigned Mayo subclass (typical classes $1\\mathrm{A}$, $1\\mathrm{B}$, $1\\mathrm{C}$, $1\\mathrm{D}$, $1\\mathrm{E}$) numerically as $1 \\rightarrow 1\\mathrm{A}$, $2 \\rightarrow 1\\mathrm{B}$, $3 \\rightarrow 1\\mathrm{C}$, $4 \\rightarrow 1\\mathrm{D}$, $5 \\rightarrow 1\\mathrm{E}$. \n\nExpress HtTKV in $\\mathrm{mL/m}$ and round your HtTKV result to four significant figures. Report your final answer as a two-entry row matrix using the LaTeX $\\mathrm{pmatrix}$ environment, with the first entry equal to the rounded HtTKV (in $\\mathrm{mL/m}$, but do not include units in the matrix) and the second entry equal to the numerical code for the Mayo subclass.", "solution": "The problem statement is evaluated for validity before proceeding to a solution.\n\n**Step 1: Extract Givens**\n- Patient diagnosis: Autosomal Dominant Polycystic Kidney Disease (ADPKD), typical phenotype\n- Total kidney volume (TKV): $950 \\ \\mathrm{mL}$\n- Standing height: $1.70 \\ \\mathrm{m}$\n- Age: $35 \\ \\mathrm{years}$\n- Task: Compute height-adjusted total kidney volume (HtTKV) and determine the Mayo imaging classification subclass.\n- Encoding for Mayo subclass: $1 \\rightarrow 1\\mathrm{A}$, $2 \\rightarrow 1\\mathrm{B}$, $3 \\rightarrow 1\\mathrm{C}$, $4 \\rightarrow 1\\mathrm{D}$, $5 \\rightarrow 1\\mathrm{E}$.\n- Rounding requirement: HtTKV must be rounded to four significant figures.\n- Final answer format: A two-entry row matrix containing the rounded HtTKV and the numerical Mayo subclass code.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded. The Mayo imaging classification for ADPKD is a well-established, validated tool used in clinical practice and research for risk stratification, based on the work of Irazabal et al. (2015, J Am Soc Nephrol). The variables (TKV, height, age) and their use in calculating HtTKV are central to this classification. The provided clinical data are plausible for an adult with ADPKD. The problem is well-posed, providing all necessary information to compute a unique solution. The language is objective and precise. The problem is therefore deemed valid.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Solution Derivation**\n\nThe primary objective is to classify the patient's disease severity using the Mayo imaging classification for typical ADPKD. This requires two main steps: first, calculating the height-adjusted total kidney volume (HtTKV), and second, comparing this value against age-specific thresholds to determine the risk subclass.\n\n1.  **Calculation of Height-Adjusted Total Kidney Volume (HtTKV)**\n    The HtTKV is a normalized metric that accounts for variations in kidney size due to patient stature. It is defined as the total kidney volume divided by the patient's height.\n\n    The given values are:\n    - Total Kidney Volume, TKV $= 950 \\ \\mathrm{mL}$\n    - Height, $h = 1.70 \\ \\mathrm{m}$\n\n    The formula for HtTKV is:\n    $$\n    \\mathrm{HtTKV} = \\frac{\\mathrm{TKV}}{h}\n    $$\n    Substituting the given values into the formula:\n    $$\n    \\mathrm{HtTKV} = \\frac{950 \\ \\mathrm{mL}}{1.70 \\ \\mathrm{m}} \\approx 558.8235... \\ \\mathrm{mL/m}\n    $$\n    The problem requires rounding the HtTKV to four significant figures.\n    $$\n    \\mathrm{HtTKV}_{\\text{rounded}} = 558.8 \\ \\mathrm{mL/m}\n    $$\n\n2.  **Determination of Mayo Imaging Classification Subclass**\n    The Mayo imaging classification stratifies patients with typical ADPKD into five risk classes ($1\\mathrm{A}$, $1\\mathrm{B}$, $1\\mathrm{C}$, $1\\mathrm{D}$, $1\\mathrm{E}$) based on their HtTKV and age. These classes correspond to predicted annual rates of TKV growth. For a patient of a given age, there are specific HtTKV thresholds (in $\\mathrm{mL/m}$) that define the boundaries between these classes.\n\n    The patient's age is $35 \\ \\mathrm{years}$. The established HtTKV thresholds (in $\\mathrm{mL/m}$) for this age are:\n    -   Class $1\\mathrm{A}$: HtTKV $< 321$ (Corresponds to predicted TKV growth $< 1.5\\%$/year)\n    -   Class $1\\mathrm{B}$: $321 \\le$ HtTKV $< 512$ (Corresponds to predicted TKV growth $1.5\\%$ to $3.0\\%$/year)\n    -   Class $1\\mathrm{C}$: $512 \\le$ HtTKV $< 793$ (Corresponds to predicted TKV growth $3.0\\%$ to $4.5\\%$/year)\n    -   Class $1\\mathrm{D}$: $793 \\le$ HtTKV $< 1208$ (Corresponds to predicted TKV growth $4.5\\%$ to $6.0\\%$/year)\n    -   Class $1\\mathrm{E}$: HtTKV $\\ge 1208$ (Corresponds to predicted TKV growth $> 6.0\\%$/year)\n\n    The patient's calculated HtTKV is $558.8 \\ \\mathrm{mL/m}$. We compare this value to the thresholds:\n    The value $558.8$ satisfies the inequality $512 \\le 558.8 < 793$.\n    Therefore, the patient is classified into Mayo Class $1\\mathrm{C}$.\n\n3.  **Encoding the Subclass and Final Answer Formulation**\n    The problem specifies a numerical encoding scheme for the Mayo subclasses: $1 \\rightarrow 1\\mathrm{A}$, $2 \\rightarrow 1\\mathrm{B}$, $3 \\rightarrow 1\\mathrm{C}$, $4 \\rightarrow 1\\mathrm{D}$, $5 \\rightarrow 1\\mathrm{E}$.\n    Since the patient's classification is Class $1\\mathrm{C}$, the corresponding numerical code is $3$.\n\n    The final answer is to be presented as a two-entry row matrix with the rounded HtTKV as the first entry and the numerical subclass code as the second.\n    -   First entry: $558.8$\n    -   Second entry: $3$\n\n    The resulting matrix is $\\begin{pmatrix} 558.8 & 3 \\end{pmatrix}$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n558.8 & 3\n\\end{pmatrix}\n}\n$$", "id": "4321955"}]}